Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGENGet Rating) in a research note issued on Sunday. The firm set a “hold” rating on the stock.

Oragenics Price Performance

OGEN opened at $0.32 on Friday. Oragenics has a fifty-two week low of $0.22 and a fifty-two week high of $0.77. The business has a 50-day moving average of $0.34 and a 200-day moving average of $0.33. The company has a market capitalization of $37.77 million, a PE ratio of -2.32 and a beta of 0.10.

Oragenics (NYSE:OGENGet Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.03) earnings per share for the quarter. The company had revenue of $0.03 million during the quarter.

About Oragenics

(Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Further Reading

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.